IACS-8803

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 408089

CAS#: 2095690-70-1

Description: IACS-8803 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8803 shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma when compared to one of the clinical benchmark compounds.


Chemical Structure

img
IACS-8803
CAS# 2095690-70-1

Theoretical Analysis

MedKoo Cat#: 408089
Name: IACS-8803
CAS#: 2095690-70-1
Chemical Formula: C20H23FN10O9P2S2
Exact Mass: 692.055
Molecular Weight: 692.5309
Elemental Analysis: C, 34.69; H, 3.35; F, 2.74; N, 20.23; O, 20.79; P, 8.95; S, 9.26

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-04. Prices are subject to change without notice.

IACS-8803 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, SDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: IACS-8803; IACS 8803; IACS8803;

IUPAC/Chemical Name: N/A

InChi Key: CMVAAKLGZJHFOY-MHDIRSDWSA-N

InChi Code: InChI=1S/C20H23FN10O9P2S2/c21-9-13-8(38-19(9)30-5-28-10-15(22)24-3-26-17(10)30)2-36-42(34,44)40-14-12(32)7(1-35-41(33,43)39-13)37-20(14)31-6-29-11-16(23)25-4-27-18(11)31/h3-9,12-14,19-20,32H,1-2H2,(H,33,43)(H,34,44)(H2,22,24,26)(H2,23,25,27)/t7-,8-,9-,12-,13-,14-,19-,20-,41-,42-/m1/s1

SMILES Code: NC1=C(C2=NC=N1)N=CN2[C@@H]3O[C@H]4[C@H]([C@H]3O[P@](S)(OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C7=C(N=C6)C(N)=NC=N7)F)O[P@](S)(OC4)=O)=O)O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 692.5309 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Ager CR, Zhang H, Wei Z, Jones P, Curran MA, Di Francesco ME. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorg Med Chem Lett. 2019;29(20):126640. doi:10.1016/j.bmcl.2019.126640



Additional Information

Activation of the stimulator of interferon genes (STING) pathway by both exogenous and endogenous cytosolic DNA results in the production of interferon beta (IFN-β) and is required for the generation of cytotoxic T-cell priming against tumor antigens. In the clinical setting, pharmacological stimulation of the STING pathway has the potential to synergize with immunotherapy antibodies by boosting anti-tumor immune responses.